Sangamo Therapeutics (NASDAQ:SGMO) has closed its sale of stock to Biogen (NASDAQ:BIIB). The company’s global licensing collaboration with Biogen for gene regulation therapies in neurology is also now effective.
Under the terms of agreement, Sangamo has received
$225M in stock proceeds and will receive an upfront license fee of
$125M no later than May 8.
Additionally, SGMO is eligible to earn up to
$2.37B in milestone payments and tiered royalties in high-single digits
to sub-teen double digits.
https://seekingalpha.com/news/3559633-sangamo-closes-gene-therapy-deal-biogen-shares-up-5-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.